Optum, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in an ...

The stock's fall snapped a four-day winning streak.

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

Marty Makary, Trump’s pick for FDA commissioner, testifies before the Senate health committee on Thursday. In 2021, Marty ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Dr. Marty Makary will testify before the Senate health committee on Thursday. Lawmakers may press him over staff reductions ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...